Empfehlungen zur Anwendung von Thalidomid bei ... - DGHO

Konsensus Thalidomid, 19. Juli 2005, Seite 42 von 51 Seiten
13. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib demonstrates
superior efficacy compared with high-dose dexamethasone, with predictable
toxicity. Haematologica 2005; 90 (s1): 146 [abstract].
14. Sonneveld P, Richardson PG, Schuster MW, et al. Bortezomib at first relapse
is superior to high-dose dexamethasone and more effective that when given
later in relapsed myeloma. Haematologica 2005; 90 (s1): 146-147 [abstract].
15. Ludwig H, Zojer N, Ackermann J, et al. Bortezomib induces remissions in
patients with relapsed/refractory myeloma independent of their cytogenetic
risk profile and addition of dexamethasone or dexamethasone plus
chemotherapy can restore responsiveness. Haematologica 2005; 90 (s1): 147
[abstract].
16. Blade J, Perales M, Rosinol L, et al. Thalidomide in multiple myeloma: lack of
response of soft-tissue plasmacytomas. Br J Haematol 2001; 113: 422-424.
17. Myers B, Grimley C, Crouch D, Dolan G. Lack of response to thalidomide in
plasmacytomas. Br J Haematol 2001; 115.234
18. Rosinol L, Cibeira MT, Blade J, et al. Extramedullary multiple myeloma
escapes the effect of thalidomide. Haematologica 2004; 89: 832-836.
19. Wu KL, Helgason HH, van der HB, et al. Analysis of efficacy and toxicity of
thalidomide in 122 patients with multiple myeloma: response of soft-tissue
plasmacytomas. Leukemia 2005; 19: 143-145.
20. Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R.
Thalidomide alone or with dexamethasone for multiple myeloma. Blood 1999;
94(S1): 604a [abstract].
21. Durie BGM, Stepan DE. Low dose thalidomide alone and in combination:
Long tern follow-up. Blood 2001; 98: 163a [abstract].
22. Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and
dexamethasone as first salvage regimen in multiple myeloma. Hematol J
2004; 5: 318-324.
23. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R.
Thalidomide and dexamethasone for resistant multiple myeloma. Br J
Haematol 2003; 121: 768-771.
24. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and
dexamethasone combination for refractory multiple myeloma. Ann Oncol
2001; 12: 991-995.
25. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein
thrombosis in patients with multiple myeloma receiving thalidomide and
chemotherapy. Blood 2001; 98: 1614-1615.
26. Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma
with thalidomide and CED chemotherapy. Blood 2001; 98: 3846-3848.